It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Cardiac arrhythmias are a primary contributor to sudden cardiac death, a major unmet medical need. Because right ventricular (RV) dysfunction increases the risk for sudden cardiac death, we examined responses to RV stress in mice. Among immune cells accumulated in the RV after pressure overload-induced by pulmonary artery banding, interfering with macrophages caused sudden death from severe arrhythmias. We show that cardiac macrophages crucially maintain cardiac impulse conduction by facilitating myocardial intercellular communication through gap junctions. Amphiregulin (AREG) produced by cardiac macrophages is a key mediator that controls connexin 43 phosphorylation and translocation in cardiomyocytes. Deletion of Areg from macrophages led to disorganization of gap junctions and, in turn, lethal arrhythmias during acute stresses, including RV pressure overload and β-adrenergic receptor stimulation. These results suggest that AREG from cardiac resident macrophages is a critical regulator of cardiac impulse conduction and may be a useful therapeutic target for the prevention of sudden death.
Cardiac immune cells play various roles in the maintenance of homeostasis and diseases in the heart. Here the authors show that cardiac resident macrophages are a critical regulator of cardiac impulse conduction through amphiregulin production, contributing to the prevention of sudden death.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Nakayama Yukiteru 1
; Matsubara Takumi 1 ; Matsuda, Jun 1
; Oshima Tsukasa 1 ; Liu, Yuxiang 1 ; Maru Yujin 1 ; Hasumi Eriko 1
; Kojima Toshiya 1 ; Seno, Hiroshi 3 ; Asano Keisuke 3 ; Ishijima Ayumu 3 ; Tomii Naoki 3 ; Yamazaki Masatoshi 3 ; Kudo Fujimi 4 ; Sakuma Ichiro 3 ; Nagai Ryozo 5 ; Manabe Ichiro 4 ; Komuro Issei 1
1 Department of Cardiovascular Medicine, the University of Tokyo, Tokyo, Japan (GRID:grid.26999.3d) (ISNI:0000 0001 2151 536X)
2 Department of Cardiovascular Medicine, the University of Tokyo, Tokyo, Japan (GRID:grid.26999.3d) (ISNI:0000 0001 2151 536X); Department of Advanced Cardiology, the University of Tokyo, Tokyo, Japan (GRID:grid.26999.3d) (ISNI:0000 0001 2151 536X); PRESTO, Japan Science and Technology Agency, Saitama, Japan (GRID:grid.419082.6) (ISNI:0000 0004 1754 9200)
3 The University of Tokyo, Medical Device Development and Regulation Research Center, Department of Bioengineering/Department of Precision Engineering, School of Engineering, Tokyo, Japan (GRID:grid.26999.3d) (ISNI:0000 0001 2151 536X)
4 Chiba University, Department of Disease Biology and Molecular Medicine, Graduate School of Medicine, Chiba, Japan (GRID:grid.136304.3) (ISNI:0000 0004 0370 1101)
5 Jichi Medical University, Tochigi, Japan (GRID:grid.410804.9) (ISNI:0000000123090000)




